Role of anti‐annexin A5 in pathogenesis of hypercoagulable state in patients with antiphospholipid syndrome
- 28 January 2013
- journal article
- research article
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 16 (3), 325-330
- https://doi.org/10.1111/1756-185x.12044
Abstract
Despite several attempts made during the last decade, the exact pathogenesis of exceedingly high thrombotic events and bad obstetric outcome in antiphospholipid syndrome (APS) remains elusive. Anti-annexin A5 (aANX IgG) is thought to have a role in pathophysiology of APS. We studied role of aANX IgG in the pathogenesis of hypercoagulable state in APS patients. We estimated levels of aANX IgG in 112 patients with APS (86 primary and 26 secondary). We also estimated aANX IgG levels in 40 age- and sex-matched healthy controls, 10 patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) each, without any history of thrombosis or pregnancy morbidity, 10 patients of non-APS thrombosis and 10 patients of pregnancy loss without APS. Only three healthy controls, two SLE (P = 0.239), one RA patient (P = 0.794), three non-APS thrombosis patients (P = 0.086) and two patients with pregnancy loss without APS (P = 0.258) had marginally elevated values, whereas 53 primary APS (P < 0.001) and 16 secondary APS (P < 0.001) were positive. We also compared aANX IgG levels in different groups. Mean ± standard errors of the mean of healthy controls was 3.77 ± 0.49, in SLE patients it was 4.88 ± 1.17 (P = 1.000), in RA patients it was 4.67 ± 0.97 (P = 1.000), in non-APS thrombosis it was 7.93 ± 0.88 (P = 0.488) and in pregnancy loss without APS it was 6.80 ± 0.93 (P = 0.789). However, it was significantly elevated in primary APS (12.87 ± 1.07, P < 0.001), secondary APS (11.98 ± 1.41, P = 0.001) and total APS patients (12.68 ± 0.88, P < 0.001). From the above observations it appears that aANX IgG plays a significant role in producing a hypercoagulable state in primary and secondary APS.Keywords
This publication has 16 references indexed in Scilit:
- Anti‐beta 2 glycoprotein 1 and anti‐annexin V antibodies in women with recurrent miscarriageBritish Journal of Haematology, 2001
- Association between the Prevalence of Antibodies to β2-Glycoprotein I, Prothrombin, Protein C, Protein S, and Annexin V in Patients with Systemic Lupus Erythematosus and Thrombotic and Thrombocytopenic ComplicationsClinical Chemistry, 2001
- Elevated Anti–Annexin V Antibody Levels in Antiphospholipid Syndrome and Their Involvement in Antiphospholipid Antibody SpecificitiesAmerican Journal of Clinical Pathology, 2000
- Antiphospholipid Antibodies Accelerate Plasma Coagulation by Inhibiting Annexin-V Binding to Phospholipids: A “Lupus Procoagulant” PhenomenonBlood, 1998
- Antiphospholipid immunoglobulin G antibodies reduce annexin-V levels on syncytiotrophoblast apical membranes and in culture media of placental villiAmerican Journal of Obstetrics and Gynecology, 1997
- Antiphosphatidylserine antibody removes annexin-V and facilitates the binding of prothrombin at the surface of a choriocarcinoma model of trophoblast differentiationAmerican Journal of Obstetrics and Gynecology, 1997
- Pregnancy Loss in the Antiphospholipid-Antibody Syndrome — A Possible Thrombogenic MechanismThe New England Journal of Medicine, 1997
- Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis.Cellular and Molecular Life Sciences, 1997
- The expression of the placental anticoagulant protein, annexin V, by villous trophoblasts: Immunolocalization and in vitro regulationPlacenta, 1994
- Antiphospholipid Antibodies and the Antiphospholipid Syndrome in Systemic Lupus Erythematosus A Prospective Analysis of 500 Consecutive PatientsMedicine, 1989